Peter Aurup

3.1k total citations · 1 hit paper
14 papers, 1.9k citations indexed

About

Peter Aurup is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Peter Aurup has authored 14 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Cardiology and Cardiovascular Medicine, 4 papers in Endocrinology, Diabetes and Metabolism and 2 papers in Surgery. Recurrent topics in Peter Aurup's work include Blood Pressure and Hypertension Studies (6 papers), Hormonal Regulation and Hypertension (4 papers) and Coronary Interventions and Diagnostics (2 papers). Peter Aurup is often cited by papers focused on Blood Pressure and Hypertension Studies (6 papers), Hormonal Regulation and Hypertension (4 papers) and Coronary Interventions and Diagnostics (2 papers). Peter Aurup collaborates with scholars based in United States, Denmark and Norway. Peter Aurup's co-authors include Björn Dahlöf, Sverre E. Kjeldsen, Stevo Julius, Markku S. Nieminen, Jonathan M. Edelman, Steven Snapinn, Hans Ibsen, Richard B. Devereux, Lars Lindholm and Ulf dé Fairé and has published in prestigious journals such as The Lancet, JAMA and Circulation.

In The Last Decade

Peter Aurup

12 papers receiving 1.8k citations

Hit Papers

Cardiovascular morbidity and mortality in patients with d... 2002 2026 2010 2018 2002 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
    2002 1.1k citations Lars Lindholm, Hans Ibsen et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Aurup United States 8 1.6k 825 216 170 160 14 1.9k
Anders Niklason Sweden 7 1.4k 0.9× 905 1.1× 199 0.9× 282 1.7× 159 1.0× 8 1.8k
Barrett W. Jeffers United States 15 1.3k 0.8× 854 1.0× 232 1.1× 224 1.3× 150 0.9× 26 1.9k
YannTong Chiang United States 13 2.0k 1.3× 865 1.0× 277 1.3× 127 0.7× 109 0.7× 21 2.5k
Patrick Brunel Switzerland 20 1.4k 0.9× 764 0.9× 277 1.3× 167 1.0× 151 0.9× 62 2.0k
Carlos Escobar Spain 22 1.4k 0.9× 404 0.5× 279 1.3× 80 0.5× 158 1.0× 199 2.0k
Allen Hester United States 19 2.6k 1.7× 949 1.2× 483 2.2× 232 1.4× 398 2.5× 26 3.1k
R Holman United Kingdom 5 732 0.5× 959 1.2× 250 1.2× 172 1.0× 65 0.4× 7 1.7k
B. Pitt United States 14 1.4k 0.9× 607 0.7× 409 1.9× 87 0.5× 61 0.4× 41 2.0k
Francis Plat United States 8 2.3k 1.4× 1.2k 1.4× 461 2.1× 274 1.6× 339 2.1× 19 2.6k
Deborah A. Price United States 20 891 0.6× 648 0.8× 115 0.5× 98 0.6× 161 1.0× 30 1.4k

Countries citing papers authored by Peter Aurup

Since Specialization
Citations

This map shows the geographic impact of Peter Aurup's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Aurup with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Aurup more than expected).

Fields of papers citing papers by Peter Aurup

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Aurup. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Aurup. The network helps show where Peter Aurup may publish in the future.

Co-authorship network of co-authors of Peter Aurup

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Aurup. A scholar is included among the top collaborators of Peter Aurup based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Aurup. Peter Aurup is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
2.
Wachtell, Kristian, Björn Hornestam, Mika Lehto, et al.. (2005). Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation. Journal of the American College of Cardiology. 45(5). 705–711. 169 indexed citations
3.
Devereux, Richard B., Kristian Wachtell, Eva Gerdts, et al.. (2003). Prognostic significance of left ventricular hypertrophy during treatment of hypertension: The LIFE study. Journal of the American College of Cardiology. 41(6). 228–228. 2 indexed citations
4.
Wachtell, Kristian, Björn Hornestam, Mika Lehto, et al.. (2003). Cardiovascular morbidity and mortality in hypertensive patients with atrial fibrillation: The LIFE study. Journal of the American College of Cardiology. 41(6). 276–276. 4 indexed citations
5.
Okin, Peter M., Richard B. Devereux, Sverker Jern, et al.. (2003). Regression of Electrocardiographic Left Ventricular Hypertrophy by Losartan Versus Atenolol. Circulation. 108(6). 684–690. 197 indexed citations
6.
Dahlöf, Björn, Alberto Zanchetti, Javier Dı́ez, et al.. (2002). Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. Journal of Hypertension. 20(9). 1855–1864. 97 indexed citations
7.
Kjeldsen, Sverre E., Björn Dahlöf, Richard B. Devereux, et al.. (2002). Effects of Losartan on Cardiovascular Morbidity and Mortality in Patients With Isolated Systolic Hypertension and Left Ventricular Hypertrophy. JAMA. 288(12). 1491–1491. 302 indexed citations
8.
Lindholm, Lars, Hans Ibsen, Björn Dahlöf, et al.. (2002). Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. The Lancet. 359(9311). 1004–1010. 1094 indexed citations breakdown →
9.
Oparil, Suzanne, Peter Aurup, Duane Snavely, & Allan I. Goldberg. (2001). Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension. The American Journal of Cardiology. 87(6). 721–726. 20 indexed citations
10.
Høst, Nis, et al.. (1995). Effect on collagen metabolism of thrombolytic therapy with tissue‐plasminogen activator. A randomized, placebo‐controlled study. European Journal of Clinical Investigation. 25(1). 15–18. 7 indexed citations
11.
Vaage‐Nilsen, Merete, et al.. (1993). The prevalence of myocardial ischemia six months after thrombolytic treatment of acute coronary episodes. A subset of a placebo controlled, randomised trial, the ASSET Study. International Journal of Cardiology. 39(3). 187–193. 1 indexed citations
12.
Galløe, Anders, Henrik Rasmussen, Lars Nannestad Jørgensen, et al.. (1993). Influence of oral magnesium supplementation on cardiac events among survivors of an acute myocardial infarction.. BMJ. 307(6904). 585–587. 12 indexed citations
13.
Aurup, Peter & Søren Højberg. (1990). [Serotonin and cardiovascular control].. PubMed. 152(39). 2840–3.
14.
Rasmussen, Henrik, R. Videbæk, Thomas Melchior, et al.. (1988). Myocardial contractility and performance capacity after magnesium infusions in young healthy persons: A double‐blind, placebo‐controlled, cross‐over study. Clinical Cardiology. 11(8). 541–545. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anders Niklason Breakdown of academic impact, for papers by Barrett W. Jeffers Breakdown of academic impact, for papers by YannTong Chiang Breakdown of academic impact, for papers by Patrick Brunel Breakdown of academic impact, for papers by Carlos Escobar Breakdown of academic impact, for papers by Allen Hester Breakdown of academic impact, for papers by R Holman Breakdown of academic impact, for papers by B. Pitt Breakdown of academic impact, for papers by Francis Plat Breakdown of academic impact, for papers by Deborah A. Price
Rankless by CCL
2026